Fig. 2From: Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based studyPercentage of patients reporting ≥ 10 acute medication days/month before and after starting eptinezumabPatients were asked: “How many days per month, on average, did you take prescribed / over-the-counter medications to treat your migraine attacks once they started? (In the 3 months before starting eptinezumab and after starting eptinezumab).” Choices included: 0, 1‒4, 5‒9, and 10 + days.Back to article page